1 Background: 2 Increased Nuchal Translucency (NT) is an important biomarker associated with increased 3 risk of fetal structural anomalies. It is known to be contributed by a wide range of genetic 4 etiologies from single nucleotide variants to those affecting millions of base-pairs. 5 Currently, prenatal diagnosis is routinely performed by karyotyping and chromosomal 6 microarray analysis (CMA), however, both of them have limited resolution. The diversity 7 of the genetic etiologies warrants an integrated assay such as genome sequencing (GS) 8
Introduction
1 Detection of fetuses with increased nuchal translucency (NT) in routine first-trimester 2 ultrasound screening has been widely used as a sensitive indication for fetal chromosomal 3 abnormalities and/or fetal structural anomalies, such as congenital heart disorders or 4 neurodevelopmental anomalies detected in later gestations (Leung et al., 2011; Huang et 5 al., 2014; Socolov et al., 2017; Sinajon et al., 2019) . Fetuses with increased NT and 6 structural malformations are frequently contributed by genetic abnormalities and have 7 poor prognoses. However, more than 80% of such cases do not obtain a causative result 8 with the current routine prenatal diagnostic tests (Leung et al., 2011; Huang et al., 9 2014; Yang et al., 2017; Sinajon et al., 2019) , challenging genetic counseling and clinical 1 0 management. In addition, pathogenic copy-number variants (CNVs) only account for 0.8 1 1
to 5.3% of these fetuses with isolated increased NT (with/without other soft markers) 1 2 (Leung et al., 2011; Huang et al., 2014) , and part of these cases would also have poor 1 3 outcomes. Therefore, a test for the comprehensive detection of disease associated 1 4 genomic variants including numerical disorders, structural rearrangements, CNVs and 1 5 point mutations in this prenatal cohort is warranted. 1 6 In prenatal diagnosis, quantitative fluorescent PCR (QF-PCR) is routinely conducted 1 7 for the detection of maternal cell contamination (MCC) and common aneuploidy [such as 1 8 Trisomy 21 (Choy et al., 2014; Sinajon et al., 2019) ]. In addition, since 2010, 1 9 chromosomal microarray analysis (CMA) has been recommended as the first-tier test for 2 0 high-risk pregnancies in identification of microscopic or submicroscopic CNVs (Leung et 2 1 al., 2011; Huang et al., 2014; Sinajon et al., 2019) . However, this approach is limited by its 2 2 resolution and it cannot detect single nucleotide variants (SNVs) and small 2 3 insertions/deletions (InDels). Owing to the breakthrough of molecular technologies such 1 as next-generation sequencing and its reduction of costs over the years, whole-exome 2 sequencing (or exome sequencing, WES) has been applied for both research purposes and 3 clinical use (Drury et al., 2015; Fu et al., 2018; Leung et al., 2018; Normand et al., 4 2018; Lord et al., 2019; Petrovski et al., 2019) . Emerging studies show WES has the 5 ability to provide genetic diagnoses ranging from 9.1% to 32% for the fetuses with a 6 structural anomaly (Drury et al., 2015; Fu et al., 2018; Leung et al., 2018; Normand et al., 7 2018; Lord et al., 2019; Petrovski et al., 2019) , while among these cases, WES yielded 8 diagnoses in 3.2% to 21% of the fetuses with increased NT with/without structural 9 malformations (Drury et al., 2015; Lord et al., 2019; Petrovski et al., 2019) . However, 1 0 most of these studies were conducted on prenatal cohorts after the exclusion of abnormal 1 1 karyotypes and/or CMA results attributed to the cost and the limited ability of WES in 1 2 CNV detection (Belkadi et al., 2015) . These studies show the clinical utility of WES and 1 3 CMA in prenatal diagnosis and warrants a combination of these two approaches for each 1 4 case. Meanwhile, both WES and CMA are unable to detect apparently balanced structural 1 5 rearrangements (or structural variants, SVs), a common limitation of the current methods 1 6 but some of these rearrangements have been demonstrated to be disease-causing 1 7 (Talkowski et al., 2012a) . The wide spectrum of genetic etiologies in fetuses with 1 8 increased NT ranging from single-base mutations to those affecting millions of base-pairs 1 9 and numerical disorders, warrants a holistic approach for comprehensive detection of the 2 0 disease-causing genetic variants. Our previous studies have demonstrated the feasibility and potential diagnostic utility 2 2 of applying low-pass whole-genome sequencing (or genome sequencing, GS) analysis in 2 3 1 NM_004333:c.G1411T(p.V471F) in BRAF gene, which was reported to cause Cardio-2 Facio-Cutaneous Syndrome (Abe et al., 2012) and Noonan Syndrome (Nystrom et al., 3 2008; Croonen et al., 2013) in an autosomal dominant manner (Table 3) . While, in 4 18NT0003, a female fetus with increased NT, hydrosarca and short limbs at the 12 th week 5 of gestation, was reported with normal CMA and karyotyping findings. A heterozygous thus it was classified as a likely pathogenic causative variant for the fetal phenotype 1 2 (Table 3) .
3
In addition, we also identified five novel mutations in four samples, including 1 4 variants in three autosomal dominant and one autosomal recessive genes ( commonly resulting in heart defects and renal malformations consistent with the 2 3 presentation of this fetus. Therefore, it was further classified as likely pathogenic (Table   1 3). Compound heterozygous point mutations were found in the fetus 14C1232: a 2 paternally inherited frameshift deletion NM_018076:c.1614_1615del(p.P538fs) and a 3 maternally inherited nonsynonymous mutation NM_018076:c.C2306A(p.P769H) were Supplementary Table S3 ). Apart from detecting CNV and point mutations, GS was able to identify structural 1 2 rearrangements by utilizing paired-end reads. Overall, two inversions and two insertions 1 3 were detected among these 50 cases ( Supplementary Table S4 ).
4
In 18NT0003 described above, GS also reported a cryptic balanced complex insertion chr12:122757221_122907271) was 150.1-kb in size but it was divided into 11 fragments 2 0 with five segments lost when inserted to chromosome 2 (Supplementary Figure S3 ).
1
There were 18 continuing nucleotide Ts found in the breakpoint junction of the inserted 2 2 sit, not belonging to either chromosomes (2 and 12) ( Figure 3D) , indicating that the 1 breakpoint repairing mechanism might be caused to non-homologous end joining with a 2 cryptic insertion (Carvalho and Lupski, 2016) . Parental confirmation by PCR and Sanger 3 sequencing established this insertion to be a paternally inherited event. Regarding the 4 potential pathogenicity, it has been known that mutations leading to loss of function in 5 BMPR2 would cause Primary Pulmonary Hypertension 1 and/or Pulmonary 6 Venooclusive Disease 1 (OMIM: #600799). However, we were unable to determine 7 whether the disruption of BMRP2 was one of the causal factors of the fetal phenotype, 8 since the pregnancy was terminated. We further followed up with the father (31-yo) and 9 found sinus bradycardia by routine electrocardiograph. Although pulmonary hypertension 1 0 may be later onset, sinus bradycardia might be one of the markers indicating pulmonary 1 1 hypertension (Rajdev et al., 2012) . Further follow-up is also on-going.
2
For the other cryptic insertion and two inversions ( Supplementary Table S4 ), since 1 3 no OMIM genes were involved and no topological associated domains were disrupted, 1 4 they were further classified as polymorphisms. For these 50 cases, 68.0% of these cases had insolated increased NT with/without other 1 7 soft markers. However, no significant difference of the diagnostic yields was found 1 8 between isolated and syndromic groups ( CMA and/or karyotyping. In addition to the identification of individual variants (i.e., SNVs, CNVs and SVs), 1 another advantage of using GS is to delineate the mutated regions involving various types 2 of aberrations. For example, in 18NT0018, a male fetus with isolated increased NT, In this study, we applied GS for 50 fetuses with increased NT with/without other fetal 2 structural malformations. In comparison, GS provided an overall diagnostic rate of 32.0%, 3 which was a 2-fold increase compared to the current prenatal diagnosis tests (16.0%).
4
Additional diagnoses include one mosaic turner syndrome, eight cases with P/LP CNVs 5 ( Table 2 ) and seven cases with P/LP point mutations ( Table 3 ). In addition, GS reported the copy-number changes by calculating the allele differences. Further confirmation of 1 6 this mosaic finding by using aCGH-based CMA platform shows the cross platform 1 7 differences of CMA testing (Haraksingh et al., 2017; Wang et al., 2019) . Of noted, in 1 8 routine setting, QF-PCR experiment was conducted prior to CMA for the detection of MCC and common aneuploidy. However, the missed detection of decreased copy-ratio of presented (Shin et al., 2016) . In addition, GS was able to delineate the 16p11.2 recurrent 2 2 deletion which included the disease-causing gene TBX6, missed detection of which in this 2 3 customized CMA platform was owing to the lack of probes located in the target region 1 (Figure 4B) . In this study, the detection results from only two CMA platforms were used 2 for comparison and the missed detections and delineations described might be limited to On top of the scope of current prenatal genetic diagnosis by karyotyping and CMA, 1 0 GS also detected seven cases with P/LP SNVs and InDels, including three known 1 1 pathogenic mutations/sites and five novel mutations (in four cases). The incidence of 1 2 P/LP mutations in this study was 14.0%, which was higher than the newly reported reason is the limited sample size or echoing the message that GS is more powerful than demonstrates the feasibility of detecting SVs by utilizing paired-end reads from GS. With 2 0 that, we were able to identify inversions and insertions and to show the potential Overall, by taking together the various genomic variants, the diagnostic rates of GS 1 4
were not significantly different between the isolated and syndromic groups ( Table 1) . For 1 5 the isolated group, GS provided a diagnostic yield as 29.4%, which was significantly 1 6 higher than the previously reported (Lord et al., 2019) . One of the reasons might be 1 7
owing to the small sample size. Nonetheless, our current data truly show a higher 1 8 diagnostic yield. Further study with larger sample size is warranted. However, there were 1 9 still 34 cases without a positive diagnosis by genome sequencing. Pregnancy outcomes 2 0 were available for 18 cases, seven (38.9%) of which were terminated pregnancies due to 2 1 severe fetal malformations, such as pleural effusion, multicystic dysplastic kidneys and 2 2 complex congenital heart disease. It indicates that genome sequencing is still not 2 3 revealing all the causative variants and the clinical decision of continuing or termination 1 of pregnancy is largely dependent on the severity of fetal malformation(s) found in each 2 particular case. Nonetheless, re-analysis of the GS data frequently upon the updating 3 literatures might be able to increase the genetic diagnosis, thus, provide the causative 4 answers for the family.
5
In this study, we aimed to evaluate the feasibility of applying GS for prenatal 6 diagnosis in the fetuses with increased NT. Apart from the increased diagnostic yield, the 7 requirement of DNA amount as input for GS (100-ng) was less, compared with CMA 8 (250-ng for CytoScan 750K or 300-ng for 8x60K Fetal Chip), which would further 9 facilitate GS in prenatal diagnosis, particularly for the AF samples from early gestational 1 0
weeks. In addition, in comparison with the methods for routine prenatal diagnosis (CMA 1 1 and karyotyping), GS would be able to provide a comparable turn-around-time of 10 1 2 working days from DNA preparation to variant validation (Figure 1) . Although the 1 3 reagent cost of GS is less than 1,000 USD per case, the demands of computational 1 4 resources and labor costs for data analysis and interpretation are still higher than routine 1 5 methods (Figure 1) . Parental confirmation is important for determination of the variants' 1 6 pathogenicity. In this study, we applied GS only for the proband and conducted the trio-based GS testing would be helpful for variant filtering in initial data analysis, it 1 9 would triplicate the cost, thus, preventing the value of clinical application.
0
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